Clinical trials: Smell Disorders
Anosmia, Covid19
Olfactory Disfunction and Co-ultraPEALut
Olfactory dysfunction is common among patients with Corona-Virus-Infection-Disease (COVID)-19, and up to 30% of patients may report persistent disorders of smell or taste as a long-term sequelae.
- Conditions
- Anosmia, Covid19, Hyposmia, Parosmia
- Trial name
- NCT04853836
- Testing
- co-ultraPEALut, Olfactory Rehab, PEA-LUT 1 sachet
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Of Perugia
COVID-19
Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19)
Participants are healthcare workers and adult outpatients referred in a COVID-19 screening center. Patients-reported symptoms are collected, then participants underwent a simple olfactory test (CODA for Clinical Olfactory…
- Trial name
- COVID-OLFA (NCT04407494)
- Testing
- Reporting of anosmia, ageusia and other clinical symptoms
- Where
- France
- Volunteers
- 809 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Alzheimer Disease, Late Onset, Mild Cognitive Impairment
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline…
- Conditions
- Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Subjective Cognitive Decline
- Trial name
- NCT06561906
- Testing
- Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Coronavirus Disease 2019
Olfactory and Neurosensory Rehabilitation in COVID-19-related Olfactory Dysfunction
A combination of oral vitamin A (VitA) and intense aromatic chemosensory smell training (ST) by pulse aromatic stimulation will expedite the neurosensory recovery of olfaction in patients suffering from prolonged COVID-19-related…
- Trial name
- NCT04900415
- Testing
- Vitamin A, Electronic portable aromatic rehabilitation (EPAR) diffuser
- Where
- 2 sites in Hong Kong
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Ivan FN Hung MD
Loss of Smell, Olfactory Disorder
Olfactory Performance in Culinary Arts Students
The COVID-19 pandemic brought impaired smell and taste to the forefront of international public awareness and clinical importance.
- Trial name
- NCT06066307
- Testing
- Olfactory training
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Leigh Sowerby
Clinical Trial
Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease
Background: Anosmia is a debilitating common symptom of COVID-19. The therapeutic effect of systemic steroid for the treatment of anosmia has been studied with various findings of its efficacy.
- Trial name
- NCT04569825
- Testing
- Ophtamesone
- Where
- Iraq
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University Of Anbar
Anxiety
"Pain and Emotional Changes on Relationships Between Anxiety and Olfaction"
Introduction: This prospective study aimed to assess the impact of olfaction on providing positive emotional responses and reducing dental anxiety and pain.
- Trial name
- NCT06066073
- Testing
- Lavender Oil, Distal Water
- Where
- Saudi Arabia
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Qassim University
Migraine Headache
Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults
A Phase I clinical trial to compare the bioavailability of dihydroergotamine mesylate (DHE) following a single dose administration of INP104 (DHE administered by I123 Precision Olfactory Delivery (POD) Device Nasal Spray) to that…
- Trial name
- NCT03401346
- Testing
- INP104, Dihydroergotamine Mesylate (DHE), Migranal Nasal Spray
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals
Epilepsy
Olfactive Discriminative Ability of Dogs When Confronted With Seizure and Non-seizure Samples // Identification of Potential Biomarkers for Epilepsy in Human Sweat.
Dogs belonging to MDD will be trained and asked to discriminate between odour sweat samples from epilepsy patients associated with a seizure ("seizure sample") and samples collected when no seizure was close in time ("non-seizure…
- Trial name
- NCT04266990
- Testing
- Planned Sweat collection, Spontaneous Sweat collection, Healthy volunteers sweat collection
- Where
- Belgium
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent